7Glasmacher A, Comely O, Ulimann A J, et al. An openlabel randomized trial comparing intraeonazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia [ J ]. J Antimicrob Chemother,2006,57:317 - 325. 被引量:1
3Richardson MD, Kokki MH. New perspectives in the diagnosis of systemic fungal infections. Ann Med, 1999,31 (2) :327. 被引量:1
4Yamakami Y, Hashimoto A, Tokimatsu I, et al. PCR detection of DNA specific for aspergillus species in serum of patients with invasive aspergillosis. J Clin Microbiol, 1996,34(10) : 2464-2468. 被引量:1
6Edmond MB,Wallace SE,McClish DK,et al.Nosocomial bloodstream infections in United States hospitals:a three-year analysis[J].Clin Infect,1999,29 (2):239-244. 被引量:1
7Bodey G,Bueltmann B,Duguid W,et al.Fungal infections in cancer patients:an international autopsy survey[J].Eur J Clin Microbiol Infect Dis,1992,11 (2):99 -109. 被引量:1
8Pfaller MA,Messer SA,Hollis RJ,et al.Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States[J].Diagn Microbiol Infect Dis,1999,33 (4):217-222. 被引量:1
9Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709. 被引量:1
10Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14. 被引量:1